“The initiative demonstrates the nation’s commitment to ending HIV by 2030, expanding access to innovative prevention tools, and reducing health inequities.”
South Africa has taken a historic step in the global fight against HIV with the official rollout of lenacapavir, a revolutionary long-acting HIV prevention injection. The programme, launched in Secunda, Mpumalanga province, positions South Africa at the forefront of HIV prevention innovation, reinforcing its reputation as a global leader in tackling the epidemic. The World Health Organization (WHO) has praised the initiative, noting that South Africa is among the first countries to move from policy to implementation, ensuring that new prevention technologies reach those who need them most.
A Breakthrough in HIV Prevention
Lenacapavir is a twice-yearly injectable pre-exposure prophylaxis (PrEP) option, designed to protect individuals at high risk of HIV infection. Unlike traditional daily oral PrEP, which requires consistent adherence, lenacapavir offers a more convenient and effective alternative. This innovation addresses one of the biggest challenges in HIV prevention: ensuring that individuals maintain consistent use of preventive medication. By reducing the burden of daily pill-taking, lenacapavir has the potential to significantly lower new HIV infections across South Africa.
National Commitment and Global Recognition
President Cyril Ramaphosa emphasized that the rollout reflects South Africa’s determination to end HIV by 2030. The government has updated its essential medicines list, secured early supplies, and prepared health systems for distribution. WHO Director-General Dr. Tedros Adhanom Ghebreyesus congratulated South Africa, stating that the rollout demonstrates “what is possible when governments, communities, and partners work together with clear purpose.”
Addressing Inequities in HIV Prevention
South Africa has one of the world’s largest HIV epidemics, with millions living with the virus and thousands of new infections reported annually. Despite decades of progress, prevention gaps remain, particularly among young women and marginalized communities. The introduction of lenacapavir is expected to reduce health inequities by expanding access to effective prevention tools for populations that have historically faced barriers to care.
Community Partnerships and Implementation
The rollout builds on South Africa’s strong tradition of community partnerships in HIV response. Civil society organizations, healthcare workers, and advocacy groups are playing a critical role in raising awareness, ensuring equitable distribution, and supporting individuals who choose lenacapavir. By integrating the injection into public health programmes, the government aims to normalize its use and encourage uptake among those most at risk.
Challenges Ahead
While the rollout is a major milestone, challenges remain. Ensuring adequate supply, training healthcare workers, and addressing stigma around HIV prevention are essential for success. Additionally, the cost of scaling up lenacapavir nationwide will require sustained investment and international support. Experts caution that while lenacapavir is highly effective, it must be part of a broader prevention strategy that includes education, testing, and treatment.
A Vision for 2030
South Africa’s rollout of lenacapavir represents a bold step toward achieving the UNAIDS target of ending HIV as a public health threat by 2030. By embracing innovation and prioritizing equity, the country is setting an example for others in the region and beyond. As Dr. Tereza Kasaeva of WHO’s Department for HIV, TB, Hepatitis and STIs noted, “South Africa’s rollout of lenacapavir demonstrates the country’s continued commitment to expanding access to innovative HIV prevention tools.”
